Novo Nordisk CEO: Don't scapegoat pricing pressure. Better drugs grow anyway

9th August 2017 Uncategorised 0

Novo Nordisk, like its rival drugmakers in diabetes, is still grappling with the pricing pressure that’s assaulted the business for a couple of years. That’s the bad news. The good? Pricing isn’t the be-all of growth. It’s portfolio.

More: Novo Nordisk CEO: Don't scapegoat pricing pressure. Better drugs grow anyway
Source: fierce